Form 4: VivoSim Labs Director Adam Stern Acquires 15,000 RSUs

VivoSim Labs Director Adam Stern reported the acquisition of 15,000 restricted stock units, bringing his total beneficial ownership to 19,899 shares.

Summary

• Director Adam K. Stern acquired 15,000 restricted stock units (RSUs) of VivoSim Labs, INC. (VIVS) common stock on January 27, 2026.
• The RSUs were acquired at a price of $0.00.
• Following this transaction, Adam K. Stern beneficially owns 19,899 shares of common stock.
• The restricted stock units are scheduled to vest on the earlier of January 27, 2027, or the date of the next annual meeting of stockholders, with acceleration upon a change of control.
• All reported share numbers in the filing give effect to a 1-for-12 reverse stock split conducted by the Issuer effective March 20, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's acquisition of equity, even through grants, generally indicates continued commitment and belief in the company's future.

Positives

• Director Adam K. Stern acquired 15,000 restricted stock units, indicating continued alignment of interests with shareholders.
• The vesting schedule for the restricted stock units includes acceleration upon a change of control, potentially incentivizing strategic transactions.

Future Outlook

The 15,000 restricted stock units are scheduled to vest on the earlier of January 27, 2027, or the date of the next annual meeting of stockholders, with potential acceleration upon a change of control.

Industry Context

StockSavvy.ai notes that insider acquisitions, even of restricted stock units, can signal management's confidence in the company's future prospects. The prior reverse stock split, while not directly part of this transaction, often occurs in companies seeking to meet listing requirements or improve stock perception, and this RSU grant reflects post-split share numbers.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) at a $0.00 price is a standard compensation practice for directors and executives, aligning their interests with long-term shareholder value, comparable to practices at companies like Apple Inc. or Microsoft Corp. for their board members.
• The vesting schedule, tied to a future date or the next annual meeting, is typical for such equity awards, promoting retention and performance, similar to the vesting structures seen in many technology and biotech firms.

Corporate Governance

Related Party Transactions

• Director Adam K. Stern received 15,000 restricted stock units as compensation, which is a transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: The director's increased equity stake aligns his interests with long-term shareholder value.

Next Steps

• Vesting of 15,000 restricted stock units on the earlier of January 27, 2027, or the date of the next annual meeting of stockholders.
• Potential acceleration of RSU vesting in the event of a change of control.

Key Dates

Recommendation

The Form 4 reports a routine grant of restricted stock units to a director, which is a standard compensation practice. While it indicates continued alignment of management's interests with shareholders, it does not provide new fundamental information to significantly alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

VivoSim Labs, VIVS, Adam Stern, Form 4, insider transaction, restricted stock units, RSU, director, stock acquisition, beneficial ownership, reverse stock split